A Chinese drug maker said it had started mass production of an experimental drug Gilead Sciences, which has the potential, the new coronavirus the fight, as China accelerates its efforts to find a treatment for the enlargement of the outbreak. Suzhou based luminous Gene Bio-Medical Technology, said in a statement to the Shanghai Stock Exchange filed on Tuesday evening that they have developed the technology to synthesize the active pharmaceutical ingredients of remdesivir, Gilead drug, which is a leading candidate of the virus highly infectious treatment which killed more than 1,000 people. The drug is not licensed or anywhere not yet released to the world. The stock rose 20% Tuesday morning trade in Shanghai. While brilliant Gene said it intends to begin the drug from Gilead, its movement at this early stage of very unusual production license and a possible violation of the intellectual property of American society. It filed an application for a week after Chinese researchers to patent new drug crown in the treatment of an offer that would provide information on the global rule of the Chinese therapy to combat the epidemic. Large parts of China have been paralyzed by the outbreak of Corona, and Gilead drugs is seen as a potential breakthrough after he showed signs of labor in the now US-Chinese patients infected with researchers 761 patients in clinical trials in Wuhan to test drug. Brilliant Gene said that the license patent Gilead carry out clinical trials and obtain regulatory approval before they can sell the drug on the market. The technology is developed to remdesivir can not be much more valuable if the drug can not produce ideal results from ongoing clinical trials, or if the epidemic is under control soon, he said. Sign up for our daily newsletter crown by clicking on this link, and send any tips, leads and [email protected] stories. Gilead did not respond to a request immediately after the announcement of the comments on the bright genes. Last week he said the company has remdesivir invented and patented in China, including applying for patents for the use of the Crown. The company also said it is working with the Chinese, US officials and the World Health Organization to quickly determine whether the drug can be used to treat the virus. bright genes do not respond immediately to requests for Bloomberg on his remdesivir production. copyright Image of Cheng Min Xinhua / Getty Images
A Chinese pharmaceutical company has started with an experimental drug for mass production COVID-19
